[250 Pages Report] The global sphingolipids market was valued at about US$ 564.0 Million in 2021, with the global market estimated to surge ahead at a CAGR of 5.1% to reach an estimated valuation of around US$ 991.8 Million by the end of 2032. Conventional lipid-based drug delivery systems (LBDDS) are driving the global sphingolipids market as of 2021, holding a 61.9% global market share.
Market Outlook:
| Data | Market Insight |
|---|---|
| Market Value 2021 | US$ 564.0 Million |
| Estimated market Value 2022 | US$ 601.3 Million |
| Estimated market Value 2032 | US$ 991.8 Million |
| CAGR of 2022 to 2032 | 5.1% |
| Market share of Top 5 countries | 66.3% |
| Key Market players | Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Others (Biosolve BV and others) |
Sphingolipids are a subclass of lipids with sphingoid bases as their backbone, a group of aliphatic amino alcohols that also includes sphingosine. Sphingolipids have many biological activities and are abundant in the central nervous system (CNS). They take part in tissue formation, cell identification, and adhesion, and function as toxin receptors. They are crucial for a number of biological functions, including differentiation, apoptosis, and signaling.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The sphingolipids market is expected to hold a market value of US$ 564.0 Million by 2032. Overall, sphingolipids market sales account for approximately 2.8% revenue share in the global pharmaceutical lipids market, which was valued at around US$ 4.4 Billion in 2021.
The global sphingolipids market recorded a CAGR of 4.7% in the historic years from 2012 to 2021.
Sphingolipids are thought of as essential excipients in the pharmaceutical as well as cosmetics industries for the production of numerous prescription drugs. They take on many different functions, including those of solubilizes, transfection agents, stabilisers, permeation enhancers, and others.
Throughout the anticipated years, the market is expected to be driven by the increasing use of semi-synthetic, synthetic, natural, or entirely man-made sphingolipids and monomers in the manufacturing of various pharmaceutical formulations.
In addition, an emerging factor driving the expansion of the worldwide sphingolipids market is enhanced drug delivery technology through prescription medications. The frequency of dispersion, level of emulsification, size of the particles, and other design elements will also contribute to the market's expansion sphingolipids market.
The manufacturing of liposomal drugs for the treatment of cancer, cardiovascular disorders, chronic illnesses, and excipients is being fuelled by the global need for pharmaceuticals. These drivers will cause the sphingolipids market to expand steadily over the forecast period.
Sphingolipids have been shown to be essential in preventing pulmonary leaks and lung injury during the past several years, and altering their routes may be a method for therapeutic interventions.
For instance, the WHO reports that dangerous and challenging-to-treat pneumonia is the most typical diagnosis among individuals with severe COVID-19 & cardiac illness. Acute respiratory distress syndrome (ARDS) is typically associated with patients who have an overactive inflammatory response.
In order to prevent the rapid clinical deterioration of individuals with COVID-19 and cardiovascular disorders, it may be necessary to take action on numerous different levels.
The aforementioned factors are expected to serve as probable market drivers for the global sphingolipids market and help the market to expand significantly in the forecast period.
Sales of pharmaceutical lipids are expected to be driven by rising demand for pharmaceutical sphingolipids, as a result of chronic diseases, the high prevalence of cancer, as well as a growing emphasis on physical well-being.
Sphingolipids appear to be strong contenders for use in the food, cosmetics, pharmaceutical, and healthcare industries. The potential of sphingolipid molecules will grow in the future as more and more new sources and structures are identified. The potential to use chemical techniques to change the structure of natural sphingolipids can also expand the range of applications for them.
Manufacturers can concentrate on creating products using natural sphingolipids, which can be extracted from biological samples and further modified chemically to produce sphingolipid compounds with novel features that are appealing to be used in cosmetic, pharmaceutical, and medical applications.
For instance, phenethyl isothiocyanate and 4-sphingosine can be coupled to have greater inhibitory activity against the proliferation of human leukaemia cells.
The abovementioned factors are capable of acting as lucrative opportunities for manufacturers operating in the sphingolipids market.
Principal Consultant
Some adverse reactions, including peripheral neuropathy brought on by paclitaxel, may be dose-limiting, further lowering the efficacy of paclitaxel chemotherapy. Radiation and chemotherapy treatments can have serious effects on young female patients' ability to conceive if their ovarian failure occurs prematurely.
Sphingolipids have been found to contribute to the side effects of cancer treatments in recent years. Sphingolipids have been demonstrated to be dysregulated in cancer and have a significant role in both cell proliferation and death.
There are more rules to control the quality and effectiveness of medications as a result of the global pharmaceutical industry's expansion. When it comes to following a nation's legal standards for the drug development process, regulatory authorities and organisations are crucial.
The standards for producing lipid-based excipients are not currently defined by any established rules. However, despite the fact that many manufacturing facilities do not follow IPEC criteria, most manufacturers generally accept them.
The above-mentioned factors can challenge the market expansion of the global sphingolipids market.
The USA held the greatest share in the regional sphingolipids market with about 94.5% share at the end of the year 2021. The biggest market for sphingolipids is the USA This is because there are numerous manufacturers in this industry and sphingolipids are in great demand across a variety of end-use sectors.
As of 2021, Germany is leading the European market withholding about 32.5% of the regional market share with a valuation of around US$ 49.7 Million. The market is primarily driven by the growing knowledge of the nutritional and functional value of sphingolipids. Synthetic sphingolipid synthesis for pharmaceutical uses increased as a result of the expanding demand for lipids, especially in Western Europe.
The market for sphingolipids is primarily driven by rising health consciousness and the resulting rise in demand for wholesome and secure food items. Consumers now place a greater emphasis on healthy eating, value quality over quantity, and choose to purchase fewer but higher-quality, more natural goods.
China has led the regional market with a massive share of about 68.6% and generated revenue of about US$113.6 Million at the end of 2021.
This is spurred on by a rise in sphingolipid demand due to their characteristics, sphingolipids, and their derivatives are highly bioactive substances with anti-cancer, bacteriostatic, and cholesterol-lowering effects. Sphingolipids are in high demand since Chinese consumers use them extensively in their everyday diet.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, sphingomyelin has driven the global market with a decent amount of market share of about 29.0% in 2021 and is expected to grow at a CAGR of 5.5%. With anti-cancer, bacteriostatic, and cholesterol-lowering characteristics, sphingolipids and their derivatives, such as sphingomyelin, are extremely bioactive substances. Owing to such properties the market for sphingomyelin is expected to grow exponentially.
By source, synthetic sphingolipids are in demand, and as of 2021, synthetic sphingolipids accounted for US$ 216.5 Million. By disrupting cell signalling, membrane trafficking, and the binding of infectious pathogens, synthetic sphingolipids offer potential as therapeutic candidates for treating a variety of disease conditions. Due to such benefits, the market is anticipated to propel in the future too.
By application, conventional lipid-based drug delivery systems (LBDDS) have driven the market by holding a majority of the market share of about 61.9% and achieved a valuation of US$ 349.1 Million at the end of 2021.
By presenting the pharmaceutical composition in a solubilized condition, as opposed to conventional tablets or powder-filled capsules, LBDDS can improve bioavailability and eliminate dissolving rate-limited absorption. The homogeneity of dosage form content may also be enhanced for medications with high potencies.
By form, semi-solids have led the market by accounting for around US$ 345.5 Million by the end of 2021. This dominance is a result of the advantage that local treatment of a variety of dermatological conditions is made possible by semi-solid dosage forms, such as topical application, with very few systemic side effects.
The probability of negative side effects is decreased when a high drug load is applied to the area where the medication is genuinely required. Topical drugs are easy for the patient to apply, and because of their nourishing qualities, semi-solid dosage forms are beneficial for a range of skin problems.
By end user, pharmaceutical companies have driven the global sphingolipids market by achieving a valuation of US$ 200.2 Million by the end of 2021. Global and diverse pharmaceutical companies have emerged. Pharma manufacturers are dominating the market with increased outsourcing, innovative modalities, and creative patient outreach strategies.
Major manufacturers are concentrating on accelerating the process to boost sales of medications containing sphingolipids. In order to lower the expenses associated with medicine development and production, they are also utilizing technical innovations.
In the upcoming years, the market is anticipated to be driven by this. The main tactics used by manufacturers to boost product sales in different locations include strategic alliances, acquisitions, expansion, new launches, agreements, and research sponsorship.
Similarly, recent developments related to companies manufacturing sphingolipids, have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Turkey, GCC, South Africa, North Africa and Rest of MEA. |
| Key Market Segments Covered | Product, Source, Form, Application, End User, and Region |
| Key Companies Profiled | Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Biosolve BV |
| Pricing | Available upon Request |
The global sphingolipids market is worth US$ 564.0 Million at end of 2021.
The sphingolipids market is expected to reach US$ 991.8 Million by end of 2032 at a CAGR of 5.1%.
Molecular and biological developments in sphingolipids providing promising health benefits and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases and cancer are some of the key factors that drive this market.
The North American region has the highest market share of about 27.6% in 2021 in the global sphingolipids market.
South Asia accounted for about 10.9% of the market share in 2021 in the global sphingolipids market.
The USA, China, Germany, and India are the top five countries, which are expected to drive demand in the sphingolipids market.
Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Biosolve BV are some of the key players in the sphingolipids industry.
From 2012 to 2021, the market for sphingolipids expanded at the rate of 4.7%.
China accounted for 68.6% of the market share at the end of 2021 in the East Asian market.
Germany displayed a market share of around 32.5% in 2021 in the European sphingolipids market
1. Executive Summary | Sphingolipids Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption-Usage Analysis 4.2. Key promotional strategies by manufacturers 4.3. Recent Launches and Approvals 4.4. Regulatory Landscape 4.5. Value chain analysis 4.6. PESTEL Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Pharmaceutical Lipids Industry Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increasing Awareness About lipids’ Health Benefits 5.2.3. Product Pricing 5.2.4. Product Availability 5.2.5. Increasing Research on Modified/Released Formulations 5.2.6. Rising Disposable Income 5.2.7. Growing Applications of Sphingolipids 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Source 6.1.3. By Application 6.1.4. By Form 6.1.5. By End User 6.2. 2021 Market Scenario 7. Global Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis, by Product, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Product, 2022 to 2032 8.4. Market Attractiveness Analysis, by Product 8.4.1. Ceramide 8.4.2. Sphingomyelin 8.4.3. Glucosylceramide (GlcCer) 8.4.4. Lactosylceramide (LacCer) 8.4.5. Ganglioside GM3 8.4.6. Other 9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Source 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, by Source, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Source, 2022 to 2032 9.4. Market Attractiveness Analysis, by Source 9.4.1. Synthetic 9.4.2. Semi-synthetic 9.4.3. Natural 10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Application, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Application, 2022 to 2032 10.3.1. Conventional Lipid-based Drug Delivery Systems (LBDDS) 10.3.2. Self-Emulsifying Drug Delivery Systems (SEDDS) 10.3.3. Self-Microemulsifying Drug Delivery Systems (SMEDDS) 10.3.4. Liposomes 10.3.5. Solid Lipid Nanoparticles 10.3.6. Nanostructured Lipid Carriers 10.3.7. Others 10.4. Market Attractiveness Analysis, by Application 11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Form 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Form, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Form, 20222032 11.3.1. Liquid 11.3.2. Semi-solid 11.3.3. Solid 11.4. Market Attractiveness Analysis, by Form 12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by End User, 2022 to 2032 12.3.1. Pharmaceutical Companies 12.3.2. Biopharmaceutical Companies 12.3.3. Academics and Research Institutes 12.3.4. Others 12.4. Market Attractiveness Analysis, by End User 13. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis, by Region, 2012 to 2021 13.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis, by Region 14. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 14.3.1. By Country 14.3.1.1. United States of America 14.3.1.2. Canada 14.3.2. By Product 14.3.3. By Source 14.3.4. By Application 14.3.5. By Form 14.3.6. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Source 14.4.4. By Application 14.4.5. By Form 14.4.6. By End User 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country-Level Analysis & Forecast 14.7.1. USA Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast, by Market Taxonomy 14.7.1.2.1. By Product 14.7.1.2.2. By Source 14.7.1.2.3. By Application 14.7.1.2.4. By Form 14.7.1.2.5. By End User 14.7.2. Canada Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast, by Market Taxonomy 14.7.2.2.1. By Product 14.7.2.2.2. By Source 14.7.2.2.3. By Application 14.7.2.2.4. By Form 14.7.2.2.5. By End User 15. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 15.3.1. By Country 15.3.1.1. Mexico 15.3.1.2. Brazil 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Product 15.3.3. By Source 15.3.4. By Application 15.3.5. By Form 15.3.6. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Product 15.4.2. By Source 15.4.3. By Application 15.4.4. By Form 15.4.5. By End User 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. Mexico Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast, by Market Taxonomy 15.7.1.2.1. By Product 15.7.1.2.2. By Source 15.7.1.2.3. By Application 15.7.1.2.4. By Form 15.7.1.2.5. By End User 15.7.2. Brazil Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast, by Market Taxonomy 15.7.2.2.1. By Product 15.7.2.2.2. By Source 15.7.2.2.3. By Application 15.7.2.2.4. By Form 15.7.2.2.5. By End User 15.7.3. Argentina Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast, by Market Taxonomy 15.7.3.2.1. By Product 15.7.3.2.2. By Source 15.7.3.2.3. By Application 15.7.3.2.4. By Form 15.7.3.2.5. By End User 16. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. Italy 16.3.1.3. France 16.3.1.4. United Kingdom 16.3.1.5. Spain 16.3.1.6. BENELUX 16.3.1.7. Russia 16.3.1.8. Rest of Europe 16.3.2. By Product 16.3.3. By Source 16.3.4. By Application 16.3.5. By Form 16.3.6. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Source 16.4.4. By Application 16.4.5. By Form 16.4.6. By End User 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. Germany Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast, by Market Taxonomy 16.7.1.2.1. By Product 16.7.1.2.2. By Source 16.7.1.2.3. By Application 16.7.1.2.4. By Form 16.7.1.2.5. By End User 16.7.2. Italy Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast, by Market Taxonomy 16.7.2.2.1. By Product 16.7.2.2.2. By Source 16.7.2.2.3. By Application 16.7.2.2.4. By Form 16.7.2.2.5. By End User 16.7.3. France Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast, by Market Taxonomy 16.7.3.2.1. By Product 16.7.3.2.2. By Source 16.7.3.2.3. By Application 16.7.3.2.4. By Form 16.7.3.2.5. By End User 16.7.4. UK Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast, by Market Taxonomy 16.7.4.2.1. By Product 16.7.4.2.2. By Source 16.7.4.2.3. By Application 16.7.4.2.4. By Form 16.7.4.2.5. By End User 16.7.5. Spain Market Analysis 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast, by Market Taxonomy 16.7.5.2.1. By Product 16.7.5.2.2. By Source 16.7.5.2.3. By Application 16.7.5.2.4. By Form 16.7.5.2.5. By End User 16.7.6. BENELUX Market Analysis 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast, by Market Taxonomy 16.7.6.2.1. By Product 16.7.6.2.2. By Source 16.7.6.2.3. By Application 16.7.6.2.4. By Form 16.7.6.2.5. By End User 16.7.7. Russia Market Analysis 16.7.7.1. Introduction 16.7.7.2. Market Analysis and Forecast, by Market Taxonomy 16.7.7.2.1. By Product 16.7.7.2.2. By Source 16.7.7.2.3. By Application 16.7.7.2.4. By Form 16.7.7.2.5. By End User 17. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Form (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Product 17.3.3. By Source 17.3.4. By Application 17.3.5. By Form 17.3.6. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Source 17.4.4. By Application 17.4.5. By Form 17.4.6. By End User 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. China Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast, by Market Taxonomy 17.7.1.2.1. By Product 17.7.1.2.2. By Source 17.7.1.2.3. By Application 17.7.1.2.4. By Form 17.7.1.2.5. By End User 17.7.2. Japan Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast, by Market Taxonomy 17.7.2.2.1. By Product 17.7.2.2.2. By Source 17.7.2.2.3. By Application 17.7.2.2.4. By Form 17.7.2.2.5. By End User 17.7.3. South Korea Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast, by Market Taxonomy 17.7.3.2.1. By Product 17.7.3.2.2. By Source 17.7.3.2.3. By Application 17.7.3.2.4. By Form 17.7.3.2.5. By End User 18. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Malaysia 18.3.1.4. Thailand 18.3.1.5. Rest of South Asia 18.3.2. By Product 18.3.3. By Source 18.3.4. By Application 18.3.5. By Form 18.3.6. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Source 18.4.4. By Application 18.4.5. By Form 18.4.6. By End User 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. India Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast, by Market Taxonomy 18.7.1.2.1. By Product 18.7.1.2.2. By Source 18.7.1.2.3. By Application 18.7.1.2.4. By Form 18.7.1.2.5. By End User 18.7.2. Indonesia Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast, by Market Taxonomy 18.7.2.2.1. By Product 18.7.2.2.2. By Source 18.7.2.2.3. By Application 18.7.2.2.4. By Form 18.7.2.2.5. By End User 18.7.3. Malaysia Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast, by Market Taxonomy 18.7.3.2.1. By Product 18.7.3.2.2. By Source 18.7.3.2.3. By Application 18.7.3.2.4. By Form 18.7.3.2.5. By End User 18.7.4. Thailand Market Analysis 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast, by Market Taxonomy 18.7.4.2.1. By Product 18.7.4.2.2. By Source 18.7.4.2.3. By Application 18.7.4.2.4. By Form 18.7.4.2.5. By End User 19. Oceania 2012 to 2021 and Forecast 2022 to 2032 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 19.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Product 19.3.3. By Source 19.3.4. By Application 19.3.5. By Form 19.3.6. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Source 19.4.4. By Application 19.4.5. By Form 19.4.6. By End User 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country-Level Analysis & Forecast 19.7.1. Australia Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast, by Market Taxonomy 19.7.1.2.1. By Product 19.7.1.2.2. By Source 19.7.1.2.3. By Application 19.7.1.2.4. By Form 19.7.1.2.5. By End User 19.7.2. New Zealand Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast, by Market Taxonomy 19.7.2.2.1. By Product 19.7.2.2.2. By Source 19.7.2.2.3. By Application 19.7.2.2.4. By Form 19.7.2.2.5. By End User 20. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032 20.1. Introduction 20.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021 20.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Turkey 20.3.1.3. South Africa 20.3.1.4. North Africa 20.3.1.5. Rest of Middle East and Africa 20.3.2. By Product 20.3.3. By Source 20.3.4. By Application 20.3.5. By Form 20.3.6. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Product 20.4.2. By Source 20.4.3. By Application 20.4.4. By Form 20.4.5. By End User 20.5. Market Trends 20.6. Drivers and Restraints - Impact Analysis 20.7. Country-Level Analysis & Forecast 20.7.1. GCC Countries Market Analysis 20.7.1.1. Introduction 20.7.1.2. Market Analysis and Forecast, by Market Taxonomy 20.7.1.2.1. By Product 20.7.1.2.2. By Source 20.7.1.2.3. By Application 20.7.1.2.4. By Form 20.7.1.2.5. By End User 20.7.2. Turkey Market Analysis 20.7.2.1. Introduction 20.7.2.2. Market Analysis and Forecast, by Market Taxonomy 20.7.2.2.1. By Product 20.7.2.2.2. By Source 20.7.2.2.3. By Application 20.7.2.2.4. By Form 20.7.2.2.5. By End User 20.7.3. South Africa Market Analysis 20.7.3.1. Introduction 20.7.3.2. Market Analysis and Forecast, by Market Taxonomy 20.7.3.2.1. By Product 20.7.3.2.2. By Source 20.7.3.2.3. By Application 20.7.3.2.4. By Form 20.7.3.2.5. By End User 20.7.4. North Africa Safety Needles Market 20.7.4.1. Introduction 20.7.4.2. Market Analysis and Forecast, by Market Taxonomy 20.7.4.2.1. By Product 20.7.4.2.2. By Source 20.7.4.2.3. By Application 20.7.4.2.4. By Form 20.7.4.2.5. By End User 21. Market Structure Analysis 21.1. Market Analysis, by Tier of Companies 21.2. Market Share Analysis of Top Players 21.3. Market Presence Analysis 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep Dive 22.3.1. Merck KGaA 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Key Financials 22.3.1.6. SWOT Analysis 22.3.1.7. Strategy Overview 22.3.2. CordenPharma International 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Key Financials 22.3.2.6. SWOT Analysis 22.3.2.7. Strategy Overview 22.3.3. Lipoid GmbH 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Key Financials 22.3.3.6. SWOT Analysis 22.3.3.7. Strategy Overview 22.3.4. LARODAN AB 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Key Financials 22.3.4.6. SWOT Analysis 22.3.4.7. Strategy Overview 22.3.5. Croda International Plc. 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Key Financials 22.3.5.6. SWOT Analysis 22.3.5.7. Strategy Overview 22.3.6. Biosynth 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Key Financials 22.3.6.6. SWOT Analysis 22.3.6.7. Strategy Overview 22.3.7. Santa Cruz Biotechnology, Inc. 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Profitability by Market Segments (Product/Channel/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Key Financials 22.3.7.6. SWOT Analysis 22.3.7.7. Strategy Overview 22.3.8. Creative Enzymes 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Profitability by Market Segments (Product/Channel/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Key Financials 22.3.8.6. SWOT Analysis 22.3.8.7. Strategy Overview 22.3.9. CD Bioparticles 22.3.9.1. Overview 22.3.9.2. Product Portfolio 22.3.9.3. Profitability by Market Segments (Product/Channel/Region) 22.3.9.4. Sales Footprint 22.3.9.5. Key Financials 22.3.9.6. SWOT Analysis 22.3.9.7. Strategy Overview 22.3.10. Cayman Chemical Company 22.3.10.1. Overview 22.3.10.2. Product Portfolio 22.3.10.3. Profitability by Market Segments (Product/Channel/Region) 22.3.10.4. Sales Footprint 22.3.10.5. Key Financials 22.3.10.6. SWOT Analysis 22.3.10.7. Strategy Overview 22.3.11. Biosolve BV 22.3.11.1. Overview 22.3.11.2. Product Portfolio 22.3.11.3. Profitability by Market Segments (Product/Channel/Region) 22.3.11.4. Sales Footprint 22.3.11.5. Key Financials 22.3.11.6. SWOT Analysis 22.3.11.7. Strategy Overview 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Sphingolipids Market
